SWOG clinical trial number
CTSU/EAY131

Molecular Analysis for Therapy Choice (MATCH)

Open
Phase
Abbreviated Title
MATCH
Status Notes
Activated: 8/12/2015, with Addendum 1.
(Pre-Activated by CTSU 5/29/2015 and SWOG on 7/15/2015). Sites must utilize CIRB as IRB of record to participate in the protocol.

***See CTSU for subprotocol status notes***
Activated
05/29/2015
Participants
CTSU

Research committees

Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Lymphoma
Melanoma
Myeloma

Eligibility Criteria Expand/Collapse

***See protocol abstract page on the CTSU website (www.ctsu.org) for each subprotocol for protocol-specific eligibility criteria.

Publication Information Expand/Collapse

2024

Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

S Gettinger;Z Song;K Reckamp;J Moscow;R Gray;V Wang;L McShane;L Rubinstein;D Patton;P Willams;S Hamilton;X Kong;J Tricoli;B Conley;C Arteaga;L Harris;P O'Dwyer;A Chen;K Flaherty JCO Precision Oncology Jul:8:e2300725

PMid: PMID38986051

2023

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

A Clark;F Hong;R Finn;A DeMichelle;E Mitchell;J Ziebel;F Arnaldez;F Arnaldez;R Gray;V Wang;L McShane;L Rubinstein;D Patton;P Willams;S Hamilton;M Copur;S Kasbari;R Thind;B Conley;C Arteaga;P O'Dwyer;L Harris;A Chen;K Flaherty Clin Cancer Res 14;29(8):1477-1483

PMid: PMID36853016 | PMC number: PMC10102836

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
21%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
31%
Open
Phase